This is an international site for Exjade® (Deferasirox) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional I am a patient inside of the US I am a patient outside the U.S.

Home > Sickle Cell Disease > Efficacy
Print

In this section:

Extension data
EU SmPC
Efficacy in Sickle Cell Disease

EXJADE Removes Toxic Iron in Patients With Sickle Cell Disease

EXJADE removes hepatic iron

23% Reduction in Liver Iron Concentration
With 30 mg/kg/day Dose1
Reductions in Mean Serum Ferritin

LONG-TERM SERUM FERRITIN
REDUCTIONS

Follow-up for the pivotal SCD trial was
extended. Learn more about the
long-term data.

Data from Study 109, a 1-year, open-label, phase II trial evaluating the safety and tolerability of EXJADE. Efficacy was measured by change in liver iron concentration (LIC) using biosusceptometry. Adjusted change (mean+SD) in LIC determined according to assigned treatment category for EXJADE.1

Effective short-term serum ferritin reductions that carry through 1 year2

Reductions in Mean Serum Ferritin With
30 mg/kg/day Dose of EXJADE1
EXJADE Reduces Hepatic Iron Concentration

Data from Study 109, a 1-year, open-label, phase II trial evaluating the safety and tolerability of EXJADE. Efficacy was measured by change in liver iron concentration (LIC) using biosusceptometry. Adjusted change (mean+SD) in LIC determined according to assigned treatment category for EXJADE.1

More Information
Extension data

References

  1. Data on file. Novartis Pharma AG, Basel, Switzerland.
  2. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501-508.
TRANSFUSION-DEPENDENT
β-THALASSEMIA		 MYELODYSPLASTIC SYNDROMES SICKLE CELL DISEASE APLASTIC AND OTHER ANEMIAS TOOLS AND RESOURCES ALL ABOUT EXJADE

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with β-thalassemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusion in patients aged 2 years and older with β-thalassemia major or other anemias when deferoxamine is contraindicated or inadequate.
Disclaimer: This is an international website for Exjade, and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
© Novartis AG | Use of this website is subject to our Terms of Use | About Novartis Oncology | Privacy | Site Map | Contact Us | EU SmPC | Safety Information | PubMed